Clinical Trial Update: MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer [Phase 2]

View source ↗

Summary

This clinical trial update reports the Phase 2 study of pemetrexed plus pembrolizumab for recurrent/metastatic salivary gland carcinoma, with the trial listed a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenoid Cystic Carcinoma
• Salivary Gland Carcinoma

Drugs mentioned

• Alimta (pemetrexed)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Mayo Clinic | Conditions: Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING